CBD has small affinity for CB receptors. It functions as an antagonist or partial antagonist at endogenous cannabinoid receptors (both CB1 and CB2 receptor styles in addition to other G-protein-coupled receptors [GPCRs]) by inhibiting entire binding of immediate ligands, and will act principally